TITLE

Abortion pill in the US

PUB. DATE
May 1991
SOURCE
New Scientist;5/25/91, Vol. 130 Issue 1770, p18
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Announces that the state legislature of New Hampshire has passed a resolution asking Roussel-Uclaf, the French company that sells RU-486, to begin clinical trials of the drug in New Hampshire. Refusal of Roussel-Uclaf to seek approval for RU-486in the US; Letter from New York Mayor David Dinkins asking other mayors to join a campaign in favor of clinical testing of the drug.
ACCESSION #
9106174633

 

Related Articles

  • U.S. drugmakers wary of RU-486.  // Drug Topics;7/5/93, Vol. 137 Issue 13, p6 

    Reports on the delayed entry to the United States market of RU-486, an abortion pill from Roussel-Uclaf. American drug companies wary of being targets of antiabortion groups.

  • Roussel Uclaf stops making abortion pill.  // Drug Topics;4/21/97, Vol. 141 Issue 8, p8 

    Reports on the decision of French pharmaceutical firm Roussel Uclaf SA to stop production of the abortion pill RU-486 to due to the drug's controversial nature and unprofitability. Transfer of patient rights for the drug to a newly formed company.

  • Hoechst withdraws drug shipments. N.T. // Chemical Week;11/20/1996, Vol. 158 Issue 45, p22 

    Reports on Hoechst subsidiary Roussel Uclaf has withdrawn active ingredients used in the manufacture of generic antibiotics. Discovery by company officials that production processes do not meet Food and Drug Administration requirements; Recall of unprocessed materials in the hands of American...

  • COMMENT: A Pill Worth Testing.  // Progressive;Dec90, Vol. 54 Issue 12, p9 

    This article discusses the impact of the drug mifepristone or RU-486. If the drug is proven to be safe and effective, it can have an enormous impact in the medical care sector. Some experts believe that the drug will be safer, cheaper and much more accessible than surgical abortion. Also, the...

  • Population council receives RU-486 patent rights.  // Nation's Health;Aug94, Vol. 24 Issue 7, p4 

    Looks at an announcement made by HHS Secretary Donna Shalala, that Roussel Uclaf has donated its US patent rights for RU-486 to the Population Council, Inc. Role of the Clinton administration; Need for clinical trials.

  • RU-486 trials to begin.  // FDA Consumer;Sep94, Vol. 28 Issue 7, p3 

    Relates plans by the Population Council, Inc. to begin clinical trials with RU-486 (mifepristone) in the fall of 1994. Actions by Roussel Uclaf; Use of RU-486 in other countries; Role of the Food and Drug Administration (FDA).

  • Company gives away RU-486 patent.  // National Catholic Reporter;04/25/97, Vol. 33 Issue 25, p9 

    Reports on the decision of Roussel Uclaf and Hoechst AG to stop manufacturing of the drug RU-486.

  • RU-486 to enter U.S. soon for multiple-use experiment. Rodgers, Katie // Drug Topics;3/7/94, Vol. 138 Issue 5, p28 

    Reports that Roussel-Uclaf's progesterone receptor antagonist, mifepristone (RU-486) could be legally imported into the United States by April 1994. Controversy surrounding the use of RU-486; Oregon Health Sciences University in Portland as potential clinical study site for the drug;...

  • Boycott threat forces French company to abandon RU486. Dorozynski, Alexander // BMJ: British Medical Journal (International Edition);04/19/97, Vol. 314 Issue 7088, p1150 

    Reports on the decision of Roussel-Uclaf to abandon production and distribution of mifepristone. Pressure from American antiabortion activists as the reason for the decision; Company's transfer of all patent rights to Edouard Sarkiz, one of the pill's developers.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics